Drugs / Pelcitoclax
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07428486 | Apr 2026 | T lymphoblastic leukemia/lymphoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT05691504 | Sep 2023 → Feb 2027 expected | endometrial carcinoma, fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma +1 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04893759 | Jan → Sep 2022 | neuroendocrine neoplasm | Ascentage Pharma Group Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04001777 | Jul 2019 → Dec 2025 overdue | non-small cell lung carcinoma | Ascentage Pharma Group Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03387332 | Dec 2017 → Nov 2020 | small cell lung carcinoma | Ascentage Pharma Group Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03080311 | Feb 2017 → Jun 2020 | small cell lung carcinoma | Ascentage Pharma Group Inc. | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07508982 | May 2026 → Dec 2029 expected | acute myeloid leukemia | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05186012 | Jun 2022 → Sep 2025 | non-Hodgkin lymphoma | Ascentage Pharma Group Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04354727 | Dec 2020 → Dec 2022 | myelofibrosis | Ascentage Pharma Group Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04210037 | Aug 2020 → Aug 2021 | small cell lung carcinoma | Ascentage Pharma Group Inc. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 11
| Date | Issuer | Release |
|---|---|---|
| 2025-06-09 | Ascentage Pharma Group Inc. | Results Thirteen Studies of Ascentage Pharma’s Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress ascentage.com ↗
Synergistic Effects of Olverembatinib (HQP1351) Combined with Bcl-2 Inhibitor Lisaftoclax (APG-2575) and Bcl-2/Bcl-xL Inhibitor Pelcitoclax (APG-1252) in T-Cell Acute Lymphoblastic Leukemia (T-ALL) |
| 2023-10-23 | Ascentage Pharma Group Inc. | Results Live from ESMO 2023 | Oral Report Featuring Latest Data of Pelcitoclax (APG-1252) Combined with Osimertinib Demonstrates Potential as a New Treatment Option for TP53-and EGFR-Mutant NSCLC ascentage.com ↗
The clinical data presented at the ESMO Congress this year demonstrated promising therapeutic utility of pelcitoclax combined with osimertinib in patients with EGFR-mutant NSCLC. |
| 2022-05-27 | Ascentage Pharma Group Inc. | Results ASCO 2022 | Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development ascentage.com ↗
Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with EGFR-mutant non-small-cell lung cancer (NSCLC). |
| 2021-12-14 | Ascentage Pharma Group Inc. | Results ASH 2021 | Ascentage Pharma Presents Latest Data from Two Studies of Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a China Study Demonstrating Complete Responses ascentage.com ↗
In an SNK-6xenograft model, administration of pelcitoclax at 65 mg/kg and 100 mg/kg either twice or once weekly resulted in significant antitumor effects, with tumor growth rate (T/C%) values ranging from 13.7% to 30.7%. |
| 2021-09-09 | Ascentage Pharma Group Inc. | Results WCLC 2021 | Mini Oral – Ascentage Pharma Announces Latest Data of Its Investigational Bcl-2/Bcl-xL Inhibitor Pelcitoclax (APG-1252) Combined with Osimertinib in Patients with EGFR TKI-Resistant Non-Small Cell Lung Cancer ascentage.com ↗
The data was presented by Prof. Li Zhang, the principal investigator of the study from Sun-Yat Sen University Cancer Center. |
| 2021-04-12 | Ascentage Pharma Group Inc. | Results Ascentage Pharma Releases Preclinical Data of Its Core Drug Candidates at AACR Annual Meeting 2021, with Results Signifying the Potential of Multiple Combination Therapies in Cancer ascentage.com ↗
Targeting BCL-xL addiction with APG-1252 (pelcitoclax) to overcome apoptotic blockade in neuroendocrine neoplasm (NEN) |
| 2021-03-10 | Ascentage Pharma Group Inc. | Results Ascentage Pharma to Present the Latest Results from Six Preclinical Studies at AACR Annual Meeting 2021 ascentage.com ↗
Targeting BCL-xL addiction with APG-1252 (pelcitoclax) to overcome apoptotic blockade in neuroendocrine neoplasm (NEN) |
| 2020-10-09 | Ascentage Pharma Group Inc. | Regulatory Ascentage Pharma’s Apoptosis-Targeting Drug Candidates Granted Two More Orphan Drug Designations by the US FDA ascentage.com ↗ |
| 2020-05-31 | Ascentage Pharma Group Inc. | Results (ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies ascentage.com ↗ |
| 2020-05-15 | Ascentage Pharma Group Inc. | Results Ascentage Pharma to Present Six Abstracts at 2020 AACR Annual Meeting ascentage.com ↗
In summary, these results suggest that the combination treatment with APG-1252 and chemotherapeutics can overcome acquired resistance to osimertinib and the combination deserves further clinical evaluations. |
| 2019-03-26 | Ascentage Pharma Group Inc. | Results Ascentage Pharma Announces Nine Abstracts To Be Presented at the 2019 American Association for Cancer Research Annual Meeting ascentage.com ↗
A Novel Bcl-2/Bcl-XL Inhibitor APG-1252-12A as A Potential Therapeutic Strategy for Gastric Carcinoma |
All press releases naming this drug 12 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pelcitoclax | “Patients received intravenous pelcitoclax (160 mg in dose-expansion and either 160 or 240 mg in dose-escalation) weekly and oral osimertinib 80 mg daily.” PMID 42442920 ↗ Jul 2026 |
| Known as | APG-1252 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04354727 ↗ |
| Action | Inhibit | “Bcl-2 family protein inhibitor” NCT03080311 ↗ |
| Modality | Small molecule | — CHEMBL4802151 ↗ |
| Route | Intravenous | “APG-1252 intravenous administration on Days 1, 4, 8, 11, 15, 18 and 22” NCT03080311 ↗ |